ASC47

歌礼制药

歌礼ASC47联合司美格鲁肽减重提升56.2%，显著改善胃肠耐受性

歌礼制药公布ASC47-103研究顶线结果：ASC47联合司美格鲁肽在肥胖患者中较单药减重效果提升高达56.2%，并降低LDL-C，改善胃肠耐受性，停药后反弹更轻。

Ascletis Pharma

Ascletis’ ASC47 Combo with Semaglutide Shows 56% Greater Weight Loss, Better GI Safety

Ascletis Pharma reported topline results from its ASC47-103 study in obesity: ASC47 plus semaglutide enhanced weight loss by up to 56.2% versus semaglutide alone, reduced LDL-C, improved GI tolerability, and showed reduced rebound post-treatment.